Teva Announces Appointment of New Chief Legal Officer
08 Novembre 2016 - 3:00PM
Business Wire
David Stark to assume position of Teva's Chief
Legal officer and succeed Richard Egosi
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)(TASE:TEVA) today
announced the appointment of Mr. David Stark to the position of
Chief Legal Officer. Stark is joining the Company’s executive
leadership team and will replace Mr. Richard Egosi, who is taking a
leave of absence.
“David has been an integral part of Teva's stellar legal team
since his arrival to Teva in 2002,” stated Erez Vigodman, Teva’s
President and CEO. “Having most recently served as Deputy Chief
Legal Officer, David led the Legal Group on a number of key
achievements including the successful negotiation and close of
Actavis Generics and Anda, and a series of key legal wins. He has
shown the leadership capabilities needed to provide Teva with the
best counsel it requires in order to deliver on its strategy,
fulfill its vision and navigate any challenges we encounter along
the way.”
Vigodman added, "Rich has been invaluable throughout his 21-year
tenure with the company and is looked upon throughout the generic
industry as an insightful and innovative thinker, due to his
success in initially propelling the US generic business to its
leadership position. Rich has been a key contributor to Teva’s
growth, providing professional expertise, guidance and insight to
both its executive management and Board, as well cultivating an
exemplary legal department. We are pleased he will continue his
career at Teva and look forward to his continued contribution and
support.”
David Stark – Key Biographical Details
David Stark has amassed over 20 years of legal experience
beginning with a series of New York law firms followed by a
distinguished career at Teva. Since joining Teva in 2002, Mr. Stark
served in a series of roles of increased responsibility in Teva
North America and Teva Americas between 2002 and 2013, including
Senior Director, Deputy General Counsel, and Vice President and
General Counsel. In 2013 he was appointed Senior Vice President and
General Counsel, Global Specialty Medicines, adding the position of
Deputy Chief Legal Officer in 2016. Between 2014 and 2015 he also
served as Acting Chief Legal Officer.
Prior to joining Teva, Mr. Stark served as an associate in the
litigation departments of Haight, Gardner, Poor & Havens
(1994-1997), Chadbourne & Parke (1997-1998), and Willkie Farr
& Gallagher (1998-2002).
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients
every day. Headquartered in Israel, Teva is the world’s largest
generic medicines producer, leveraging its portfolio of more than
1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2015 amounted to $19.7
billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are
based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our specialty
products, especially Copaxone® (which faces competition from
orally-administered alternatives and a generic version); our
ability to integrate Allergan plc’s worldwide generic
pharmaceuticals business (“Actavis Generics”) and to realize the
anticipated benefits of the acquisition (and the timing of
realizing such benefits); the fact that following the consummation
of the Actavis Generics acquisition, we are dependent to a much
larger extent than previously on our generic pharmaceutical
business; potential restrictions on our ability to engage in
additional transactions or incur additional indebtedness as a
result of the substantial amount of debt incurred to finance the
Actavis Generics acquisition; the fact that for a period of time
following the Actavis Generics acquisition, we will have
significantly less cash on hand than previously, which could
adversely affect our ability to grow; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters;
our ability to achieve expected results from investments in our
pipeline of specialty and other products; our ability to identify
and successfully bid for suitable acquisition targets or licensing
opportunities, or to consummate and integrate acquisitions; the
extent to which any manufacturing or quality control problems
damage our reputation for quality production and require costly
remediation; increased government scrutiny in both the U.S. and
Europe of our patent settlement agreements; our exposure to
currency fluctuations and restrictions as well as credit risks; the
effectiveness of our patents, confidentiality agreements and other
measures to protect the intellectual property rights of our
specialty medicines; the effects of reforms in healthcare
regulation and pharmaceutical pricing, reimbursement and coverage;
competition for our generic products, both from other
pharmaceutical companies and as a result of increased governmental
pricing pressures; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability,
major hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with
internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant
disruptions of our information technology systems or breaches of
our data security; competition for our specialty pharmaceutical
businesses from companies with greater resources and capabilities;
the impact of continuing consolidation of our distributors and
customers; decreased opportunities to obtain U.S. market
exclusivity for significant new generic products; potential
liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that
are not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial
talent; any failures to comply with complex Medicare and Medicaid
reporting and payment obligations; significant impairment charges
relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting
reliance on access to the capital markets; potentially significant
increases in tax liabilities; the effect on our overall effective
tax rate of the termination or expiration of governmental programs
or tax benefits, or of a change in our business; variations in
patent laws that may adversely affect our ability to manufacture
our products in the most efficient manner; environmental risks; and
other factors that are discussed in our Annual Report on Form 20-F
for the year ended December 31, 2015 and in our other filings with
the U.S. Securities and Exchange Commission (the "SEC").
Forward-looking statements speak only as of the date on which they
are made and we assume no obligation to update or revise any
forward-looking statements or other information, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161108005674/en/
Teva Pharmaceutical Industries Ltd.IR:United StatesKevin C.
Mannix, 215-591-8912Ran Meir,
215-591-3033orIsraelTomer Amitai, 972 (3)
926-7656orPR:IsraelIris Beck Codner, 972 (3)
926-7687orUnited StatesDenise Bradley, 215-591-8974
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024